Zevra Therapeutics Inc
NASDAQ:ZVRA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
Z
|
Zevra Therapeutics Inc
NASDAQ:ZVRA
|
485.2m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
591.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
292.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
244.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Zevra Therapeutics Inc
Glance View
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 36 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. The company employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Zevra Therapeutics Inc is 41.9%, which is above its 3-year median of -234.5%.
Over the last 3 years, Zevra Therapeutics Inc’s Net Margin has increased from -328.5% to 41.9%. During this period, it reached a low of -549.1% on Mar 31, 2023 and a high of 41.9% on Sep 30, 2025.
